Quotient Sciences Header

Quotient Sciences Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Sosei Heptares","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Breezhaler\u00ae Approval in the European Union as a Treatment for Uncontrolled Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"},{"company":"Sosei Heptares","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sosei Heptares Notes Enerzair\u00ae Approval in Japan","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Approved","country":"JAPAN","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Sosei Heptares"}]

Sosei Heptares

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sosei Heptares Notes Enerzair® Breezhaler® Approval in the European Union as a Treatment for Uncontrolled Asthma

Details:

European Commission approves once-daily Enerzair® Breezhaler® in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with LABA/ICS1.

Lead Product(s): Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Enerzair Breezhaler

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 07, 2020

ASK
US

Upload
your Pipeline Activity

Sosei Heptares

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Sosei Heptares Notes Enerzair® Approval in Japan

Details:

For the first time in Japan, a new digital device combining a sensor with the Breezhaler® inhaler is being made available. Announcement by Novartis Pharma K. K. highlights key milestone for once-daily Enerzair® (IND/GLY/MF) complete with new sensor-enabled Breezhaler® device.

Lead Product(s): Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Enerzair Breezhaler

Highest Development Status: Approved Product Type: Small molecule

Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 29, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY